Survival Benefit of Adjuvant Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma Who Underwent Surgery Following Neoadjuvant FOLFIRINOX
Cancer Research and Treatment · 15.07.2023 · 55 (3) · 956-968
DOI: 10.4143/crt.2022.409 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Research and Treatment, erschienen am 15.07.2023. Verfasst von So Heun Lee und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal, Adenocarcinoma. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: Asan Institute for Life Sciences, Asan Medical Center.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Purpose
The benefit of adjuvant chemotherapy following curative-intent surgery in pancreatic ductal adenocarcinoma (PDAC) patients who had received neoadjuvant FOLFIRINOX is unclear. This study aimed to assess the survival benefit of adjuvant chemotherapy in this patient population.Materials and Methods This retrospective study included 218 patients with localized non-metastatic PDAC who received neoadjuvant FOLFIRINOX and underwent curative-intent surgery (R0 or R1) between January 2017 and December 2020. The association of adjuvant chemotherapy with disease-free survival (DFS) and overall survival (OS) was evaluated in overall patients and in the propensity score matched (PSM) cohort. Subgroup analysis was conducted according to the pathology-proven lymph node status.
Results
Adjuvant chemotherapy was administered to 149 patients (68.3%). In the overall cohort, the adjuvant chemotherapy group had significantly improved DFS and OS compared to the observation group (DFS: median, 13.8 months [95% confidence interval (CI), 11.0 to 19.1] vs. 8.2 months [95% CI, 6.5 to 12.0]; p < 0.001; and OS: median, 38.0 months [95% CI, 32.2 to not assessable] vs. 25.7 months [95% CI, 18.3 to not assessable]; p=0.005). In the PSM cohort of 57 matched pairs of patients, DFS and OS were better in the adjuvant chemotherapy group than in the observation group (p < 0.001 and p=0.038, respectively). In the multivariate analysis, adjuvant chemotherapy was a significant favorable prognostic factor (vs. observation; DFS: hazard ratio [HR], 0.51 [95% CI, 0.36 to 0.71; p < 0.001]; OS: HR, 0.45 [95% CI, 0.29 to 0.71; p < 0.001]).
Conclusion
Among PDAC patients who underwent surgery following neoadjuvant FOLFIRINOX, adjuvant chemotherapy may be associated with improved survival. Randomized studies should be conducted to validate this finding.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
- Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
- Department of Hematology and Oncology, Chungnam National University Hospital, Daejeon, Korea.
- Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
- Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Förderung
- Asan Institute for Life Sciences, Asan Medical Center
Zitieren
APA
Lee, S. H., Hwang, D. W., Yoo, C., Kim, K. P., Kang, S., Jeong, J. H., Oh, D., Song, T. J., Lee, S. S., Park, D. H., Seo, D. W., Park, J. H., Song, K. B., Lee, J. H., Lee, W., Park, Y., Kwak, B. J., Chang, H. M., Ryoo, B. Y., & Kim, S. C. (2023). Survival Benefit of Adjuvant Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma Who Underwent Surgery Following Neoadjuvant FOLFIRINOX. Cancer Research and Treatment, 55(3), 956-968. https://doi.org/10.4143/crt.2022.409
Vancouver
Lee SH, Hwang DW, Yoo C, Kim KP, Kang S, Jeong JH, et al. Survival Benefit of Adjuvant Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma Who Underwent Surgery Following Neoadjuvant FOLFIRINOX. Cancer Research and Treatment. 2023;55(3):956-968. doi:10.4143/crt.2022.409
BibTeX
@article{Lee2023,
author = {Lee, So Heun and Hwang, Dae Wook and Yoo, Changhoon and Kim, Kyu-Pyo and Kang, Sora and Jeong, Jae Ho and Oh, Dongwook and Song, Tae Jun and Lee, Sang Soo and Park, Do Hyun and Seo, Dong Wan and Park, Jin-Hong and Song, Ki Byung and Lee, Jae Hoon and Lee, Woohyung and Park, Yejong and Kwak, Bong Jun and Chang, Heung-Moon and Ryoo, Baek-Yeol and Kim, Song Cheol},
title = {Survival Benefit of Adjuvant Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma Who Underwent Surgery Following Neoadjuvant FOLFIRINOX},
journal = {Cancer Research and Treatment},
year = {2023},
volume = {55},
number = {3},
pages = {956--968},
doi = {10.4143/crt.2022.409}
}
EUVIMED